Cellect secures stem cell-based therapy patent

By The Science Advisory Board staff writers

August 6, 2020 -- Cellect Biotechnology has secured a European patent for its stem cell selection technology. The patent was also approved in Australia and Israel, according to the firm.

European patent No. 14851547.1 will expire in October 2034. It covers the regenerative capacity of stem and progenitor cells in the company's Apograft cell-based blood product. Importantly, it protects the intellectual property of the second component of Apograft involving the activation of stem and progenitor cells.

Cellect currently holds 45 patents, it said.


Copyright © 2020 scienceboard.net
 

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?